Microbot Medical Inc. announced on August 5, 2025, that it has been approved to receive a non-dilutive grant from the Israel Innovation Authority (IIA). The grant amounts to NIS 2.15 Million, which is approximately $630,000 at a recent exchange rate.
This funding is intended to further strengthen the company’s manufacturing capabilities, positioning it to successfully implement the commercialization of the LIBERTY System. The grant is contingent upon marketing clearance by the U.S. Food and Drug Administration (FDA).
The IIA's decision acknowledged Microbot Medical's recent milestone achievements, the target market characteristics, the competitive advantages of a single-use, disposable robot, and the expected benefits of the LIBERTY System. This grant validates the company's technology and reflects confidence in its ability to scale manufacturing and meet business objectives.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.